0.00Open0.99Pre Close0 Volume1 Open Interest0.50Strike Price0.00Turnover457.97%IV-0.67%PremiumNov 15, 2024Expiry Date1.00Intrinsic Value100Multiplier15DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9503Delta0.0729Gamma1.43Leverage Ratio-0.0048Theta0.0002Rho1.36Eff Leverage0.0003Vega
Opko Health Stock Discussion
MT Newswires· 1 min ago
OPKO Health (OPK) subsidiary ModeX Therapeutics said Monday it has been awarded an additional $35 million in funding under a contract with the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority to develop Covid-19 and flu vaccines.
NextPlat: Four-Year Extension of OPKO Healthcare E-Commerce Program in China
Entera Bio and OPKO Health Provide Update on Pk/Pd Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
Conference call begins at 4:30 p.m. Eastern time today
MIAMI (August 7, 2024) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2024.
Highlights from the second quarter and recent weeks include the following:
●
Enrollment underway in the MDX2001 Phase 1 trial for the treatment of solid...
No comment yet